Table 2 Normative data of the CFS by age and gender
X (SD) | M (25–75%) | X (SD) | M (25–75%) | X (SD) | M (25–75%) | |
|---|---|---|---|---|---|---|
Female | 20–29 age (n = 126) | 30–40 age (n = 86) | 20–40 age (n = 212) | |||
CFS-PF | 8.6 (3.9) | 8 (6–12) | 8.5 (3.6) | 8 (6–11) | 8.6 (3.8) | 8 (6–11.5) |
CFS-MF | 3.8 (7.7) | 4 (2–5) | 3.6 (1.9) | 4 (2–5) | 3.7 (1.8) | 4 (2–5) |
CFS | 12.3 (4.9) | 12 (9–16) | 12 (4.8) | 12 (8–15) | 12.2 (4.8) | 12 (9–16) |
Male | 20–29 age (n = 160) | 30–40 age (n = 104) | 20–40 age (n = 264) | |||
CFS-PF | 6.3 (3.4) | 7 (4–8) | 6.4 (3.3) | 7 (4–8) | 6.3 (3.4) | 7 (4–8) |
CFS-MF | 3.2 (1.9) | 3 (2–4) | 2.9 (1.7) | 3.5 (1–4) | 3.1 (1.8) | 3 (1–4) |
CFS | 9.5 (4.7) | 10 (6–12) | 9.3 (4.6) | 11 (5–11.5) | 9.4 (4.6) | 10 (6–12) |
Overall | 20–29 age (n = 286) | 30–40 age (n = 190) | 20–40 age (n = 476) | |||
CFS-PF | 7.3 (3.8) | 7 (4–10) | 7.4 (3.6) | 7 (5–9) | 7.3 (3.7) | 7 (5–10) |
CFS-MF | 3.4 (1.8) | 4 (2–4) | 3.2 (1.9) | 4 (1–4) | 3.3 (1.8) | 4 (2–4) |
CFS | 10.7 (5) | 11 (7–14) | 10.6 (4.8) | 11 (7–14) | 10.7 (4.9) | 11 (7–14) |